金沙app旧版

Annual Report and Form 20-F
金沙官网手机下载app

01

金沙官网手机下载app

In 2018, we achieved a significant milestone by returning to 产品介绍 Sales growth. In 2019, we refreshed our strategy to focus on what comes next, and where we want our business to be in 2025. Our strategy reflects ideas which we crowdsourced from our employees and is underpinned by the initiatives outlined below which are intended to accelerate delivery of our strategy.


02

金沙官网手机下载app


In the first full year of our return to 产品介绍 Sales growth, we made good progress in line with our strategy. We anticipate 2020 to be another year of progress.

Leif Johansson, Chairman

AstraZeneca’s first full year of returning to 产品介绍 Sales growth was made possible by our ability to deliver our science to patients. We are now maximising and exploring the full potential of our leading medicines, rapidly advancing the next wave of science and positioning your Company for continued success.

Pascal Soriot, Chief Executive Officer

03

金沙官网手机下载app

2019 generated accelerating 产品介绍 Sales growth from outstanding New Medicine uptake, driving an increase to Core Operating profit.


金沙app旧版


Total Revenue*                                   
金沙app旧版

$24.4bn金沙app旧版


Net cash flow from operating activities
Up 13% at actual rate of exchange to $2,969 million                                   



金沙app旧版

$3.0bn金沙app旧版

// Denotes a scale break. All bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other.

*Total Revenue consists of Product Sales and Collaboration Revenue.

 

金沙app旧版


Reported operating profit
金沙app旧版


$2.9bn金沙app旧版


Core operating profit
金沙app旧版


$6.4bn金沙app旧版

金沙app旧版


Reported EPS
金沙app旧版


$1.03金沙app旧版


Core EPS
金沙app旧版


$3.50金沙app旧版



04

金沙官网手机下载app

We are a global, science-led, patient-focused, pharmaceutical company. We have transformed our pipeline and returned to growth. As a result of continued pipeline delivery and commercial execution, we are now entering a new stage in our journey.


金沙官网手机下载app


Total Product Sales

$23,565m金沙app旧版

2018: $21,049m
2017: $20,152m

 

金沙官网手机下载app

金沙官网手机下载app


金沙官网手机下载app


金沙app旧版

金沙app旧版

金沙app旧版

金沙app旧版

金沙app旧版

金沙app旧版

金沙app旧版

金沙app旧版



金沙官网手机下载app


Dividends
金沙官网手机下载app

$3,592m金沙app旧版

2018: $3,484m
2017: $3,519m
金沙app旧版


Proceeds from issue of shares1金沙官网手机下载app

$(3,525)m金沙app旧版

2018: $(34)m
2017: $(43)m
金沙app旧版


Total
金沙官网手机下载app

$67m金沙app旧版

2018: $3,450m
2017: $3,476m

金沙app旧版


 1. In April 2019, the Company completed a placing of 44,386,214 new Ordinary Shares of $0.25 each in the Company.


金沙官网手机下载app

05

金沙官网手机下载app

At AstraZeneca, health is our business and our contribution to society. How we operate supports sustainable ecosystems for healthcare that benefit people and our planet through science-based innovation.

Our aspiration is for the future to be healthy and that we are an active participant for a healthy society, planet and business. Our pioneering medicines touch the lives of millions of people so it is a business imperative that we are partners and activists for solutions to global health. At the heart of our sustainability approach is access to healthcare and its connection to environmental protection, and ethics and transparency.



More information


More information


More information